{"id":138754,"title":"hVIVO Target Implies 270% Upside as Orderbook More Than Doubles","publisher":"Share Talk","author":"sharetalk","published":"2026-07-23T16:20:24+00:00","modified":"2026-07-23T16:20:24+00:00","canonical_url":"https://www.share-talk.com/hvivo-target-implies-270-upside-as-orderbook-more-than-doubles/","markdown_url":"https://www.share-talk.com/hvivo-target-implies-270-upside-as-orderbook-more-than-doubles.md","json_url":"https://www.share-talk.com/hvivo-target-implies-270-upside-as-orderbook-more-than-doubles.json","category":"Blogs","categories":["Blogs","Health","Healthcare","Pharmaceutical"],"tags":["Andrew Catchpole","antiviral","breast cancer","Canary Wharf","Cathal Friel","CHIMagents","clinical respiratory drug","Codagenix","COVID-19","Dengue Fever","Dr Andrew Catchpole","Dr Chris Chiu","Gregory Stoloff","hVIVO","Imperial College London","Imutex Ltd","laboratory","Malaria","Open Orphan","ORPH","Oxford BioTherapeutics","pharmaceutical","quarantine clinic","Rahim Fandi","Share Talk","Stephen Pinkerton","The Lancet","Vaccine","virology","West Nile Virus","Yamin 'Mo' Khan","Zika"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2026/07/hvo-23-july-26.jpg?fit=1200%2C630&quality=89&ssl=1","format":"news","language":"en-GB","content":"hVIVO’s order book has more than doubled to [£65 million](https://www.share-talk.com/hvivo-orderbook-more-than-doubles-as-commercial-momentum-rebuilds/), prompting Shore Capital to reiterate its Buy rating and 25p target price.\n\nThe updated target compares with a current share price of 6.8p, implying potential upside of around 270%.\n\nThe broker’s positive stance comes despite the company facing a steep second-half delivery challenge.\n\nhVIVO reported first-half revenue of £16.3 million, with full-year performance expected to be heavily weighted towards the second half.\n\nThe company said the enlarged orderbook provides improved revenue visibility for the rest of 2026 and into 2027 and 2028.\n\nProposal volumes were also around 45% higher year-on-year, supporting expectations for further commercial momentum.\n\nShore Capital’s reiterated target suggests the broker remains focused on the strength of the orderbook and the medium-term growth opportunity, rather than the weaker first-half revenue and EBITDA profile.\n\nThe key test for hVIVO will now be whether it can convert the strengthened orderbook into second-half revenue delivery and a return to positive adjusted EBITDA."}